DOE Patents title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Peptides having reduced toxicity that stimulate cholesterol efflux

Abstract

The present invention provides a family of non-naturally occurring polypeptides having cholesterol efflux activity that parallels that of full-length apolipoproteins (e.g., Apo AI and Apo E), and having high selectivity for ABCA1 that parallels that of full-length apolipoproteins. Further, the peptides of the invention have little or no toxicity when administered at therapeutic and higher doses. The invention also provides compositions comprising such polypeptides, methods of identifying, screening and synthesizing such polypeptides, and methods of treating, preventing or diagnosing diseases and disorders associated with dyslipidemia, hypercholesterolemia, or inflammation; or diseases involving abnormal glucose metabolism, e.g., diabetes, metabolic syndrome; or Alzheimers Disease or frontotemporal dementia.

Inventors:
;
Issue Date:
Research Org.:
Lawrence Berkeley National Laboratory (LBNL), Berkeley, CA (United States)
Sponsoring Org.:
USDOE; National Institutes of Health (NIH)
OSTI Identifier:
1840354
Patent Number(s):
11091529
Application Number:
15/511,623
Assignee:
The Regents of the University of California (Oakland, CA)
Patent Classifications (CPCs):
A - HUMAN NECESSITIES A61 - MEDICAL OR VETERINARY SCIENCE A61K - PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
C - CHEMISTRY C07 - ORGANIC CHEMISTRY C07K - PEPTIDES
DOE Contract Number:  
AC02-05CH11231; HL085791
Resource Type:
Patent
Resource Relation:
Patent File Date: 09/14/2015
Country of Publication:
United States
Language:
English

Citation Formats

Bielicki, John K., and Johansson, Jan. Peptides having reduced toxicity that stimulate cholesterol efflux. United States: N. p., 2021. Web.
Bielicki, John K., & Johansson, Jan. Peptides having reduced toxicity that stimulate cholesterol efflux. United States.
Bielicki, John K., and Johansson, Jan. Tue . "Peptides having reduced toxicity that stimulate cholesterol efflux". United States. https://www.osti.gov/servlets/purl/1840354.
@article{osti_1840354,
title = {Peptides having reduced toxicity that stimulate cholesterol efflux},
author = {Bielicki, John K. and Johansson, Jan},
abstractNote = {The present invention provides a family of non-naturally occurring polypeptides having cholesterol efflux activity that parallels that of full-length apolipoproteins (e.g., Apo AI and Apo E), and having high selectivity for ABCA1 that parallels that of full-length apolipoproteins. Further, the peptides of the invention have little or no toxicity when administered at therapeutic and higher doses. The invention also provides compositions comprising such polypeptides, methods of identifying, screening and synthesizing such polypeptides, and methods of treating, preventing or diagnosing diseases and disorders associated with dyslipidemia, hypercholesterolemia, or inflammation; or diseases involving abnormal glucose metabolism, e.g., diabetes, metabolic syndrome; or Alzheimers Disease or frontotemporal dementia.},
doi = {},
journal = {},
number = ,
volume = ,
place = {United States},
year = {2021},
month = {8}
}

Works referenced in this record:

Prevention and treatment of restenosis by local administration of drug
patent, February 2012


Peptides Having Reduced Toxicity Thar Stimulate Cholesterol Efflux
patent-application, September 2014


Peptide mediators of cholesterol efflux
patent, April 2013


Helical synthetic peptides that stimulate cellular cholesterol efflux
patent-application, September 2005


Potent and Selective Mediators of Cholesterol Efflux
patent-application, December 2012